Some advancement on the herpes vaccine front: San Diego biotech Vical recently kicked off a Phase 1/2 trial of its Vaxfectin genital herpes vaccine – a therapeutic inoculation that’s melded vaccine and DNA technologies.Here’s how it works: Vical’s approach directs the immune response in two ways: It teaches immune cells to develop weapons against the herpes […]
Many companies are contending to hit the market first in the race for a genital herpes vaccine(Opens in a new window). The thread that ties them together? Immunotherapy – the wunderdrug for cancer therapy that’s now showing promise(Opens in a new window) for infectious disease.But it hasn’t always been so, said Agenus CEO Garo Armen, whose immunotherapy approach […]
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Cambridge pharmaceutical maker Genocea(Opens in a new window) remains at the head of the herpes vaccine pack, having newly released another set of positive results for its experimental HSV2 vaccine. The company has found that its herpes vaccine is effective even a year after the initial dosage – cutting down the genital lesion and viral shedding rates substantially […]
After decades of stagnancy in the herpes therapeutics space, a real neck-and-neck race is emerging among three biotechs in the immunotherapy space: Genocea(Opens in a new window) and Agenus(Opens in a new window), both based in Massachusetts, San Diego’s Vical(Opens in a new window) are speeding ahead in developing a herpes vaccine.The idea for these companies is […]